Big pharma and COVID-19: Balancing social commitments and profits

It is quite possible that the attempt to treat COVID-19 will bear out as the peak of pharmaceutical research and development in human history. The race is on, replete with attempts at a vaccine and repurposing of drugs — many of them from rheumatology — to mitigate the infection at various stages. However, millions of potential patients and unprecedented demand presents big pharma

Read the full article here

Related Articles